1-6 of 6
Eileen Farrelly
Close
Sort by
Journal Articles

Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)

Larysa Sanchez, MD, Dasha Cherepanov, Dorothy Romanus, RPh, PhD, Aditya Raju, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-136597
Published: 2020
Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1827.
https://doi.org/10.1182/blood-2019-121658
Published: 2019
Journal Articles

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Ajai Chari, MD, Dorothy Romanus, Katarina Luptakova, MD, Aditya Raju, MS, Eileen Farrelly, MPH, Marlo Blazer, PharmD, Tomas Skacel, MD, Parameswaran Hari, MD MRCP, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1818.
https://doi.org/10.1182/blood.V130.Suppl_1.1818.1818
Published: 2017
Journal Articles

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Sharanya Murty, PhD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS
Journal: Blood
Blood (2017) 130 (Supplement 1): 2167.
https://doi.org/10.1182/blood.V130.Suppl_1.2167.2167
Published: 2017
Journal Articles

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Marlo Blazer, PharmD, BCOP, Brian Seal, RPh, MBA, PhD, Huai-Che Shih, PhD, Augustina Ogbonnaya, MPH, Michael Eaddy, PharmD, PhD, Bruce J Dezube, MD
Journal: Blood
Blood (2016) 128 (22): 5540.
https://doi.org/10.1182/blood.V128.22.5540.5540
Published: 2016
Journal Articles

Evaluation of Cardiovascular Disease Risk in Chronic Myelogenous Leukemia Patients Using Electronic Medical Records from Community-Based Oncology Practices in the United States

Anna O. D'Souza, B.Pharm, PhD, Dinara Makenbaeva, MD MBA, Eileen Farrelly, MPH, Pamela Landsman-Blumberg, MPH, DrPH, Bjorn Bolinder, MSc,MBA
Journal: Blood
Blood (2015) 126 (23): 4478.
https://doi.org/10.1182/blood.V126.23.4478.4478
Published: 2015